外源性α-Synuclein通过p-NMDAR2B/Nur77诱导多巴胺类神经元的氧化损伤
Xiaoyi Lai1, Jiannan Wu1, Xuanfen Kou2
1Key Laboratory of Neuromolecular Biology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Molecular neurobiology
|November 26, 2024
概括
阿尔法-同核素 (α-syn) 纤维素通过通过p-NMDAR2B/Nur77通路增加氧化应激导致帕金森病 (PD) 运动缺陷. 这项研究揭示了PD病变发生的一个新机制.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔法-同核素 (α-syn) 聚合是帕金森病 (PD) 病原体的核心.
- 氧化应激显著导致PD中多巴胺基神经元退化.
- 连接α-syn与PD的精确分子机制仍然不完全理解.
研究的目的:
- 研究帕金森病中α-syn预形成纤维素 (α-syn PFFs) 的病理机制.
- 探索NMDAR2B和Nur77在α-syn诱导的氧化应激和多巴胺基神经退行症中的作用.
- 为了确定PD的潜在治疗点.
主要方法:
- 使用α-syn PFFs构建体内 (小鼠条状体注射) 和体内 (SH-SY5Y细胞) PD模型.
- 行为分析,西式涂抹,免疫光学和流动细胞测量以评估病理变化.
- 研究了抑制p-NMDAR2B和过度表达Nur77对氧化应激和细胞活力的影响.
主要成果:
- 在小鼠中,α-syn PFF诱导了运动缺陷,增加了pS129-α-syn和α-syn寡合体,减少了TH表达,并加剧了氧化应激.
- 在α-syn PFF模型中观察到NMDAR2B和p-NMDAR2B的升高水平,Nur77的降低.
- 抑制p-NMDAR2B或Nur77过度表达改善了α-syn PFF诱导的氧化应激,线粒体损伤和细胞毒性.
结论:
- α-syn PFFs在多巴胺基神经元中诱导帕金森病类病理和氧化应激.
- p-NMDAR2B/Nur77通路参与调解α-syn诱导的氧化应激.
- 准p-NMDAR2B/Nur77通路可能为帕金森病提供一种新的治疗策略.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482


